marijuana stocks

Tetra Bio-Pharma Discusses Development of PPP003 Drug for Cytokine Reduction with The Stock Day Podcast

Jolly began the interview by asking about the Company’s recent announcement regarding their PPP003 inflammatory Cytokine reduction drug program. “I think this is a very interesting time to be living in as a company,” said Dr. Chamberland, noting that before COVID-19 the Company had been assisting other businesses in applying for drug approvals. Dr. Chamberland then shared that a division of the Company had been researching the effectiveness of PPP003 in Cytokine reduction since 2014, and is now shifting even more of its focus and energy into this program. “Our drug is not going to cure covid, it is not an antiviral. What it does is help to reduce what we call the ‘exaggerated anti-inflammatory response’, which puts a lot of patients at risk,” explained Dr. Chamberland.

“This drug has not been tested in humans. We’re hoping to do that later this year,” said Dr. Chamberland, adding that the Company has revamped and accelerated its development program. “As a company, we want to make sure this drug is safe to give to healthy volunteers first,” he continued. “We’ve taken a very strict approach to this.”

“We’ve even teamed up for the first Phase II trial in patients with a US company, Onegevity Health,” shared Dr. Chamberland. “It’s going to be a very interesting development that we’ll be keeping shareholders informed about as we move forward.”

“How is the formulation of the PPP003 different from the one being used for Uveitis?,” asked Jolly. “The ones we use for Uveitis are basically eye drops,” explained Dr. Chamberland. “This is going to be an intravenous injection,” he continued. “It’s the same active medicinal ingredients, the only difference is now one goes towards an eye drop for the finished product and the Cytokine form goes towards an injectable drug.”

“I understand that you are developing some sort of program that would allow Tetra to treat COVID-19 infected patients, is that correct?”, asked Jolly. Dr. Chamberland explained that the Company’s primary concern is the safety of its patients, which is why human testing will begin with healthy volunteers. “If it is clean, then we will allow it to be used in patients,” said Dr. Chamberland.

The conversation then turned to the Company’s current valuation and any changes that could occur over the next few months. “I don’t know how much we’ll go up, I don’t know how much any of this will have an impact between now and even Christmas,” said Dr. Chamberland. “As a CEO, I’m keeping my focus on developing the drugs the way the FDA and NIH would expect us to do, and keeping our team’s focus on trying to contribute to the fight against the Cytokine storm if we can and then we’ll worry about the stock price afterwards,” closed Dr. Chamberland.

To hear Dr. Guy Chamberland’s entire interview, follow the link to the podcast here: https://audioboom.com/posts/7576389-tetra-bio-pharma-discusses-development-of-ppp003-drug-for-cytokine-reduction-with-the-stock-day-p

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSXV: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed and approved, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Investor Contact:

Alpha Bronze, LLC

Mr. Pascal Nigen

Phone: + 1 (646) 255-0433

tetra@alphabronze.net

Public Relations:

Energi PR

Ms. Carol Levine

Phone: + 1 (514) 288-8500 ext. 226

carol.levine@energipr.com

About The “Stock Day” Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:

Stock Day Media

(602) 821-1102

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/55521


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Better Choice Company Inc. (BTTR) to Announce Fourth Quarter and Full Year 2022 Financial Results

Better Choice to Announce Fourth Quarter and Full Year 2022 Financial Results…

$VHUB Announces Radio Interview with President and CEO

Vapor Hub International Executives Interviewed By The Stock Radio SIMI VALLEY, Calif.,…

Future Farm Technologies Inc. (FFRMF) Strategic Partner BCWC, LLC Selected as One of 20 Applicants to Receive Priority Certification

Future Farm’s Strategic Partner BCWC, LLC Selected as One of 20 Applicants…

$CBDS Announces Raising $300,000 To Cover Short Term Expenses

Cannabis Sativa, Inc. Announces Raising $300,000 To Cover Short Term Expenses Cannabis…